Genzyme, a Sanofi company, has received approval from the Australian Therapeutic Goods Administration (TGA) for Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis (RRMS) for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses. Lemtrada 12 mg has a novel dosing and administration schedule of two annual treatment courses. The first treatment course of Lemtr...